Efavirenz: Resistance and cross-resistance

International Journal of Clinical Practice, Supplement

Volumn , Issue 103, 1999, Pages 21-25

  Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLONE; CONFERENCE PAPER; CROSS RESISTANCE; GENE MUTATION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS REPLICATION; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; REVIEW;

ANTI-HIV AGENTS; DELAVIRDINE; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NEVIRAPINE; OXAZINES; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 0032585902     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Saag MS, Hahn BH, Gibbons J et al. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1998; 334: 440-444.
2. Richman DD. Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. In : Mills H, Ed. Antiviral Chemotherapy 4. New York: Plenum Press; 383-395.
3. Wainberg MA, Gu Z, Gao Q et al. Clinical correlates and molecular basis of HIV drug resistance. J Acquir Immune Defic Syndr 1993; 6: S36-S46.
4. Gunthard H, Wong J, Ignacio C et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72: 2422-2428.
5. Wong JK, Hezareh M, Gunthard H et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viraemia, Science 1997; 278: 1291-1295.
6. Finzi D, Hermankova M, Pierson T et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
7. Kempf DJ, Rode RA, Xu Y et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9-F14.
8. Raboud JM, Montaner JS, Conway, B et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998; 12: 1619-1624.
9. Mellors J. Defining reponse and optimising therapy: the role of new technologies. In: Changing treatment paradigms towards optimal patient care. London: Meditech.
10. Hirsh MS, Conway B, D'Aquila RT. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998; 279: 1984-1991.
11. Havlir D, Hicks C, Kahn J et al. Durability of antiviral activity of efavirenz (EFV, DMP 266) in combination with indinavir (IDV) [DMP 266-003, Cohort IV]. (Poster I-104) 38th ICAAC, San Diego, September 1998.
12. Mayers D, Jemesk J, Eyster E et al. A double-blind, placebo-controlled study to assess the safety, tolerability and antiretroviral activity of efavirenz (EFV, SUSTIVA™, DMP 266) in combination with open-label zidovudine (ZDV) and lamivudine (3TC) in HIV-1 infected patients [DMP 2660-04] (Poster 22340) 12th World AIDS Conference, Geneva, June 1998.